Adam Golden

About Adam Golden

Adam serves as global head of life sciences. Based in New York, he advises clients on M&A, licenses and collaborations, venture capital financings and commercial transactions in the life sciences sector. A dual M&A and IP transactions lawyer, Adam has deep experience representing pharmaceutical, biotech and medical device companies and investors on a broad range of transactions, including hybrid deals such as M&A transactions with back-end milestone payments, carve-outs, options to acquire or license and product divestitures. He also regularly advises clients on related transition service, manufacturing and supply, and other operational agreements.

Adam is recognized as a leading life sciences practitioner by Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, Lawdragon, LMG Life Sciences, IFLR1000 and IAM Patent 1000. He has been shortlisted as M&A Attorney of the Year and Life Sciences Star by LMG Life Sciences, and a Life Sciences MVP by Law360.

Recent work

Select M&A Transactions

• CVC on its $925m acquisition of Therakos from Mallinckrodt.
• Grünenthal on its acquisition of Valinor Pharma and its product Movantik® (naloxegol).
• Merz Therapeutics on its $185 million acquisition of Acorda Therapeutics. 
• Basilea Pharmaceutica on its acquisition from Pfizer of Fosmanogepix, a clinical-stage antifungal candidate with a novel mechanism of action to treat invasive mold infections.
• Roivant Sciences on its $7.1 billion sale of Telavant to Roche.
• Novartis in its acquisition of DTx Pharma, a biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
• Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics, Inc.
• Moderna on its acquisition of OriCiro Genomics K.K
• Rayner Surgical on its acquisition of the product OMIDRIA^® from Omeros Corporation in a transaction valued in excess of $1 billion.
• Ipsen on the sale to Fusion Pharmaceuticals of rights to a radiopharmaceutical developed for oncology indications.
• Novartis on its acquisition of Cadent Therapeutics, a clinical-stage neuroscience company.
• Engrail Therapeutics on its acquisition of NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation.
• Novartis on its acquisition of Vedere Bio, including a platform for AAV-based delivery of gene therapies and an optogenetics program.
• Altavant Sciences on its acquisition of Onspira Therapeutics, a private drug development company focused on therapeutics for rare pulmonary diseases.
• Bausch Health on its option to purchase the ophthalmology assets of Allegro Pharmaceuticals.
• Novartis on its acquisition of IFM Tre for up to $1.6bn and its option to acquire IFM Due for up to $840m.
• Celgene on its $9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.
• Novartis on its $8.7bn acquisition of AveXis, a clinical-stage gene therapy biotech company.
• Celgene on its acquisition of Impact Biomedicines for up to $7bn, a clinical stage company developing fedratinib for myelofibrosis.
• Chase Pharmaceuticals on its sale to Allergan for up to $1bn.
• Alcon Laboratories on its acquisitions of Encore Vision, RxSight and Transcend Medical.
• Bausch Health on the sale of Dendreon Pharmaceuticals to Sanpower.

Select License and Collaboration Transactions

• Novartis on its exclusive strategic license agreement with Arvinas, Inc., a clinical-stage biotechnology company, for the global development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for prostate cancer patients. 
• AbbVie on its collaboration and option agreement with Parvus Therapeutics to develop and commercialize treatments for IBD, utilizing Parvus’ proprietary Navacim^TM platform technology.
• Novartis on its license agreement with Legend Biotech for the exclusive worldwide rights to develop, manufacture and commercialize certain chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3. 
• Novartis in its $1.3 billion technology transfer agreement with Chong Kun Dang, a leading Seoul-based pharmaceutical company, for the exclusive global rights (except Korea) to develop and commercialize CKD-510, a new drug candidate developed by CKD.
• Novartis on its collaboration and license agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of a novel medicine for patients with certain cardiovascular diseases.
• SERB Pharmaceuticals in its acquisition of exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ Pharmaceuticals.
• Novartis on its global co-development and co-commercialization agreement with UCB for Parkinson’s Disease therapies.
• Spark Therapeutics on its collaboration and option agreement with Senti Biosciences with respect to the development of next-generation precision gene therapies.
• Novartis on its exclusive worldwide license and collaboration agreement with Mesoblast Limited to develop remestemcel-L for the treatment of acute respiratory distress syndrome, including that associated with COVID-19.
• Gilead Sciences on a license agreement with Xencor for the use of XmAB® antibody technologies in investigational agents for HIV.
• Gilead Sciences on its strategic collaboration with Tango Therapeutics to develop and commercialize innovative targeted immuno-oncology treatments for cancer.
• Kite, a Gilead company, on an up to $3bn deal to access Sangamo Therapeutics’ zinc finger nuclease technology.
• Celgene on strategic collaborations with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics and Skyhawk Therapeutics.
• Gilead Sciences on its $150m collaboration with Agenus to develop and commercialize novel immuno-oncology therapies.
• Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.
• Novartis on strategic collaborations with Sangamo Therapeutics, Surface Therapeutics, Xencor and Homology Medicines.